New Neurocognitive/Functional Morbidity Explored in SARS-CoV-2, MIS-C
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 12, 2024 -- Children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome in children (MIS-C) with severe neurological manifestations are more likely to have new neurocognitive and/or functional morbidity at hospital discharge, according to a study published online June 10 in JAMA Network Open.
Conall Francoeur, M.D.C.M., from the McGill University Health Center in Montreal, and colleagues conducted a prospective cohort study involving 3,568 patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C (83.5 and 16.5 percent, respectively) between Jan. 2, 2020, and July 31, 2021. The primary outcome was new neurocognitive and/or functional morbidity at hospital discharge.
The researchers found that 18.0 and 24.8 percent of the patients with acute SARS-CoV-2 and MIS-C, respectively, had a severe neurological manifestation during hospitalization. The likelihood of having new neurocognitive or functional morbidity at hospital discharge was higher among survivors with acute SARS-CoV-2 with versus without severe neurological manifestations (27.7 versus 14.6 percent); similar findings were seen for patients with MIS-C (28.0 versus 15.5 percent). The odds of having new neurocognitive and/or functional morbidity at hospital discharge were increased for patients with acute SARS-CoV-2 and those with MIS-C after adjustment for risk factors in those with severe neurological manifestations (odds ratios, 1.85 and 2.18, respectively).
"Future studies should aim to better understand the pathophysiology behind the severe neurological manifestations and to investigate the role of surveillance, treatment, and follow-up of these patients with high risk of neurocognitive and/or functional morbidities," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Further Support and Information on COVID-19
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.